06955 BOAN BIOTECH
- 9.150
- -0.110-1.19%
BOAN BIOTECH News
China Accepts Boan Biotechnology's Biologics License Application for Type 2 Diabetes Drug
China's medical products administrator accepted Shandong Boan Biotechnology's (HKG:6955) biologics license application for its BA5101 dulaglutide injection for type 2 diabetes patients in China, accor
Boan Biotech (06955.HK): Dulacopeptide Injection (BA5101) application accepted for listing in China
Gelonghui, May 27丨Boan Biotech (06955.HK) announced that the marketing application for the company's self-developed duracopeptide injection (BA5101) has been accepted by the Drug Evaluation Center of the China National Drug Administration. BA5101 is a biosimilar to Trulicity for blood sugar control in adults with type 2 diabetes. As far as the company knows, BA5101 is currently the first Trulicity (Trulicity) biosimilar to be submitted for marketing in China, and the first Trulicity (Trulicity) biosimilar in the world to complete phase III clinical trials
Shandong Boan Biotechnology GCTB Drug NMPA's Marketing Approval
Shandong Boan Biotechnology (HKG:6955) said China's National Medical Products Administration (NMPA) approved its denosumab injection (120mg) for marketing, according to a Monday filing on the Hong Ko
Boan Biotech's Boluojia Wins NMPA Approval
Boan Biotech (06955.HK) in the field of oncology has been approved and marketed for the treatment of bone giant cell tumors that cannot be surgically resected or where surgical resection may cause serious dysfunction
On May 27, Ge Longhui | Boan Biotech (06955.HK) announced that the company's self-developed dysulumab injection (120mg) - Boroga has been approved by the China National Drug Administration for the treatment of bone giant cell tumors that cannot be surgically removed or may cause serious functional impairment, including adults and young patients with mature bone development (defined as at least 1 mature bone and body weight greater than 45 kg). Boroga is a biosimilar of Agave (English product name: XGEVA). Its development process strictly follows biosimilar relationships in China, the United States, the European Union, and Japan
博安生物：2023年度報告
Boan Biotech (06955.HK) was granted a loan financing of 300 million yuan
Gelonghui, April 12, 丨 Boan Biotech (06955.HK) announced that on April 12, 2024, the company entered into a loan financing agreement with China Jingu International Trust Co., Ltd. (the “Lender”). Based on this, the lender agreed to provide the Company with a term loan of RMB 300 million. The board of directors believes that this financing will help advance the company's development strategy, enable the company to rapidly develop and market various products, and potentially accelerate the pace of successful commercialization. The financing is in line with the company's long-term goals and leverages the huge market potential of its product pipeline. The company is preparing to use this financing to effectively enhance its business operations, thereby investing in shares
Selected announcements | China's non-ferrous mining industry plans to sell up to 163 million shares at a discount of about 13.54%; Longyuan Electric Power's power generation will increase by about 10% during the year
China's net profit for the first quarter was 2,308 billion yuan, up 0.33% year on year; Qiutai Technology sold about 368.39 million mobile phone camera modules in March, up 31.8% from month to month, down 1.7% year on year.
Shandong Boan Biotechnology Completes Phase 3 Trial for Retina Injection
Shandong Boan Biotechnology (HKG:6955) completed its China phase 3 trial for its Aflibercept intravitreous injection indicated for retina and choroid pathological neovascular ophthalmopathy, accordin
Boan Biotech (06955.HK): Abbasip intraocular injection solution (BA9101) completed phase III clinical trials in China and plans to submit a marketing application
Boan Biotech (06955.HK) announced that the abacip intraocular injection solution (“BA9101”) developed by the company has completed phase III clinical trials (clinical efficacy and safety comparison test) in China and plans to submit a marketing application. Abacept is a homologous dimer glycoprotein formed by fusing the extracellular domain of human vascular endothelial growth factor receptor (VEGFR1Ig2 region and VEGFR2Ig3 region) with the Fc domain of human IgG1. It is a soluble inducer receptor that can bind to VEGF-A, VEGF-B, and PlGF, and can inhibit endogenous V
Shandong Boan Biotechnology Trims Attributable Loss in 2023
Shandong Boan Biotechnology (HKG:6955) said its loss attributable to owners narrowed to 119.4 million yuan in 2023 from 331.75 million yuan in 2022, according to a filing with the Hong Kong bourse on
Boan Biotech (06955) announced annual results. Shareholders' losses of 119 million yuan narrowed by 64.02% over the same period last year. It has been granted 35 patents and 45 pending patent applications worldwide
Boan Biotech (06955) announced its annual results for the year ended December 31, 2023. The group achieved revenue of 618 million yuan (RMB, same below) during the period, an increase of 19.8% over the previous year; loss attributable to shareholders was 119 million yuan, a year-on-year decrease of 64.02%; and a basic loss of 0.23 yuan per share.
Boan Biotech (06955.HK)'s annual revenue of about 618 million yuan increased 19.8% year-on-year
Gelonghui, March 25 | Boan Biotech (06955.HK) announced that for the year ended December 31, 2023, the Group's revenue was approximately RMB 618.1 million, an increase of 19.8% over the previous year. This increase is mainly due to increased sales of Boyunuo (BA1101) and Boyoubi (BA6101) in China. For the year ended 31 December 2023, the Group recorded gross profit of approximately RMB 408.9 million, an increase of 15.4% over the previous year. For the year ended 31 December 2023, the Group confirmed R&D expenditure of approximately RMB 230.7 million, compared to the end of 20
BOAN BIOTECH: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Boan Biotech (06955.HK) will hold a board meeting on March 25 to approve the annual results
Gelonghui March 12 | Boan Biotech (06955.HK) announced that the company will hold a board meeting on March 25, 2024 to approve the company's annual results for the year ended December 31, 2023 and consider declaring a final dividend (if any).
BOAN BIOTECH: NOTICE OF BOARD MEETING
Shandong Boan Biotech Completes Phase 3 Trial for Type 2 Diabetes Injection; Shares Surge 10%
Shandong Boan Biotechnology (HKG:6955) completed its phase 3 trial for the dulaglutide injection for type 2 diabetes and plans to file its biologics license application for the drug, according to a fi
Boan Biotech (06955.HK): Dulacopeptide Injection (BA5101) completed phase III clinical trials in China and plans to submit a marketing application
On March 8, Ge Longhui Biotech (06955.HK) announced that the company's self-developed duracopeptide injection (“BA5101”) has completed phase III clinical trials (clinical efficacy, safety and immunogenicity comparison studies) in China and plans to submit a marketing application. BA5101 is a biosimilar to Trulicity for blood sugar control in adults with type 2 diabetes. As far as the company knows, BA5101 is the world's first duracopeptide biosimilar to complete phase III clinical trials, leading the development progress. Dulacopeptide is a long-acting glucagon-like
Shandong Boan Biotechnology Authorizes CDMO Service Provider to Use Stable Cell Line Development Platform
Shandong Boan Biotechnology (HKG:6955) has entered into an agreement to allow Zencore Biologics to use its self-developed stable cell line development platform BA-HIEXcell to develop antibodies and t
Boan Biotechnology, Joincare Sign Exclusive License Deal for Respiratory Disease Treatment
Shandong Boan Biotechnology (HKG:6955) will grant Joincare Pharmaceutical Group Industry (SHA:600380) exclusive rights to develop, register, manufacture, and sell its BA2101 drug for chronic obstructi
Analysis
Price Target
No Data
